摘要:
The process development of Mavatrep (1), a potent transient receptor potential vanilloid-1 (TRPV1) antagonist; is described. The two key synthetic transformations are the synthesis of (E)-6-bromo-2-(4-(trifluoromethyl)styryl)1H-benzo[d]imidazole (4) and the Suzuki coupling of 4 with 3,3-dimethyl-3H-benzo,[c][1,2]oxaborol-1-ol (5). Compound 1a was prepared in four chemical step in 63% overall yield.